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Objective: To examine the impact of temporary and permanent weight loss of 10% and 15% on 10-year and
lifetime Medicare spending among adults with overweight and obesity aged 65 years and older. Weight loss of this
magnitude is consistent with next generation anti-obesity medications recently approved by the Food and Drug
Administration.
Methods: We follow the approach of a longitudinal dynamic aging process model developed by our research
team. This model considers the dynamic relationships between weight, chronic disease, acute medical events,
functional status, mortality, health care utilization and spending among Medicare beneficiaries from age 65 until
death. Using this model, we estimate baseline Medicare spending over the next decade and then over the lifetime
of seniors with a body mass index (BMI) ≥ 27 with at least one weight-related comorbidity (overweight), and
seniors with obesity having a BMI ≥ 30 and ≥ 35. We then estimate Medicare spending for this population
between ages 65 and 70 over the course of a year, assuming 10% and 15% weight loss under alternative scenarios:
with and without weight regain. (Weight regain is assumed to be 90% over a 10-year period.) The difference in
spending between baseline (no weight-loss intervention) and the alternative scenarios represent potential gross
savings to the Medicare program.
Results: Permanent weight loss of 10 to 15% will yield $9,445 to $15,987 in gross per capita savings throughout
their lifetime, and $8,070 to $13,474 over ten years. Similarly, initial weight loss of 10 to 15% followed by 90%
weight regain will result in gross per capita savings of $7,556 to $11,109 over their lifetime, and $6,456 to $8,911
over ten years. Targeting weight loss medications to adults with obesity (BMI ≥ 30) produces greater savings to the
Medicare program.
Conclusion: Medicare can realize significant cost savings through anti-obesity medications that produce substantial
weight loss, and as a result, reduce the progression to type 2 diabetes, and improve blood pressure and glycemic
indicators in hypertensive and diabetic patients, respectively. Medications are currently excluded from coverage in
the Medicare program, however, in light of potential savings and health benefits, may warrant consideration.Background
Obesity has been linked to a wide array of chronic health
care conditions, including diabetes, hypertension, hyper-
lipidemia, cancer, heart disease, and musculoskeletal and
pulmonary disorders, among others. The higher preva-
lence of chronic disease results in higher health care
spending. In any given year, adults with obesity spend
approximately 40% more on health care than normal
weight adults [1,2], and people with diabetes spend 2.3
times more than people without diabetes [3]. Lifetime* Correspondence: longassociatesva@aol.com
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in any medium, provided the original work is pspending is also higher among overweight adults. Two
recent studies have estimated that lifetime Medicare
spending for adults starting at age 65 are 15–35% higher
among adults with obesity as compared to normal weight
adults [4,5]. There is substantial evidence supporting
the beneficial effects of weight loss with respect to both
obesity-related comorbid risk factors and mortality, which
is why the National Institutes of Health (NIH) has esta-
blished a weight loss target of 10% body weight from base-
line within six months [6]. Unfortunately, there have been
relatively few effective, long-term treatment options to
choose from, as evidenced by the significant paucity
of available treatments to fill the gap between lifestylean Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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dications with better efficacy profiles have been FDA-
approved for chronic weight management; however,
reimbursement policies that are founded on a legacy of
safety and efficacy concerns with previous anti-obesity
medications are currently an impediment to access. Our
hypothesis is that interventions designed to reduce the
incidence and prevalence of overweight and obesity, or
lower weight among adults with obesity, could both im-
prove health outcomes and lower health care spending.
This study is the first to project the potential impact
that a new generation of anti-obesity medications may
have on both short term (10-year) and lifetime spending
among the Medicare population (adults aged 65 and
older) who are either overweight with at least one
weight-related comorbidity (such as hypertension or dia-
betes) or are obese. Estimated savings are based on 10%
and 15% weight loss, as recent clinical trials have shown
these results to be attainable based on Intent-to Treat
(ITT) and Completers analyses, respectively. We esti-
mate these savings under five scenarios: baseline sce-
nario without weight loss intervention; 10% and 15%
initial weight loss followed by 90% weight regain over a
10-year period (i.e., “temporary” weight loss); and 10%
and 15% permanent weight loss. The estimated savings
assume Medicare would add weight loss drugs as a co-
vered benefit; they currently are not. Estimated gross per
capita savings do not include the costs of medications to
the Medicare program, however, the impact of antici-
pated drug costs are included in the Discussion section.
The primary health benefits associated with weight
loss include the long-term risk reduction for acute med-
ical events as well as a reduction in the incidence of
chronic disease. Hence, we estimated savings over the
beneficiaries’ lifetime and over 10 years, as only evaluat-
ing immediate cost benefits would under estimate the
value of weight loss intervention.
Methods
The analysis presented below follows the approach of a
Dynamic Aging Process (DAP) model developed by Yang
[5]. This model profiles and approximates the dynamic
aging process that involves the development of chro-
nic diseases, deterioration of health status, fluctuation of
body mass index, and Medicare expenditures for each
beneficiary from age 65 to death. Using this approach,
Yang and Hall demonstrate that lifetime Medicare
spending among normal weight adults is about 17%
lower than adults with obesity [5]. This model pro-
duces lifetime costs of obesity that are approximately
50% lower than a previous estimation from the Rand
Future Expenditure (FEM) model using the same data
source [4]; thus, we view the results of cost savings pre-
sented below as conservative.To understand the lifetime Medicare savings from one
year of baseline weight loss, we assume two scenarios
that could bound the potential savings. First we assume
initial weight loss of 10% and 15%, and based on the
10 year follow up of the diabetes prevention program
(DPP), we assume 90% of the weight is regained over
10 years [7]. These scenarios produce the most conser-
vative cost-savings estimates because weight regain in
the DPP was both expected and observed with lifestyle
modification. The one- and two-year clinical trials for a
recently approved anti-obesity drug (phentermine/topi-
ramate ER) provide no rationale for weight regain with
on-going use of the medication, however, estimating
some degree of weight regain provides a lower bound
for cost savings. The second estimate assumes a sus-
tained reduction in weight, which is consistent with
2-year published data demonstrating sustained weight
loss with treatment adherence [8]. Recent evidence sug-
gests physiologic mediators are responsible for the
weight re-gain that often follows weight loss induced by
lifestyle modification [9]. Therefore, much the way anti-
hypertensive agents are maintained after a patient rea-
ches a target blood pressure, or lipid-lowering drugs are
maintained after reaching a cholesterol target, it is an-
ticipated that a patient will need to continue on anti-
obesity treatment indefinitely to maintain weight loss.
Using the DAP model described above, and following
the previous publication by Yang and Hall, we first used
Medicare Current Beneficiary Survey (MCBS) data from
1992 to 2001 to obtain the average 10-year and lifetime
per capita Medicare expenditures as the baseline sce-
narios without any weight control intervention. We pre-
sent estimates for 2012 to 2021 using the Congressional
Budget Office projections of per capita Medicare spend-
ing [2]. Next, we conducted counter factual simulation
under alternative scenarios, assuming those with BMI ≥
27 and one weight-related comorbidity at age 65 lose
10% or 15% of their body weight, and calculated the ave-
rage 10-year and lifetime per capita expenditures under
the two scenarios (with and without weight rebound).
Taking the differences between the 10-year and lifetime
expenditures for the baseline and alternative scenarios,
we obtained the average gross per capita savings for both
temporary and permanent 10% and 15% weight loss. We
repeated the analysis for a cohort of adults with class I
(BMI ≥ 30) and class II (BMI ≥ 35) obesity.
Results
Table 1 illustrates the differences in Medicare savings
under each of the scenarios relative to baseline (no weight
loss intervention). The first two columns depict savings
based on temporary weight loss (10% and 15%) followed
by 90% weight regain, and the last two illustrate the sa-
vings associated with permanent weight loss (10% and
Table 1 Lifetime and 10-year gross per capita Medicare savings from temporary and permanent weight loss among
one cohort age 65–70
Baseline BMI at age 65 10% Weight loss with weight
regain (“Temporary”)






BMI ≥ 27 + co-morbidity (2.4 million*)
Lifetime $7,556 $9,933 $9,445 $12,912
10 Years $6,456 $7,831 $8,070 $10,180
BMI ≥ 30 (5.5 million*)
Lifetime $9,112 $10,304 $12,392 $14,116
10 Years $7,446 $8,911 $9,053 $12,208
BMI ≥ 35 (3.3 million*)
Lifetime $7,799 $11,109 $13,496 $15,987
10 Years $7,654 $8,534 $10,126 $13,474
*These numbers reflect the number of Medicare beneficiaries within each BMI category, which can be used to determine the available pool of aggregate savings.
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of the respective rows reflects the number of Medicare
beneficiaries represented by each BMI category.)
These results demonstrate that permanent weight loss
of 10–15% among adults with class I obesity (BMI ≥ 30)
results in gross per capita lifetime Medicare savings
of $12,392–$14,116 or $9,053–$12,208 over a 10-year
period. Weight loss of that magnitude followed by 90%
weight regain yields gross per capita lifetime Medicare
savings of $9,112–$10,304 or $7,446–$8,911 over a
decade.
For adults with class II obesity (BMI ≥ 35), we found
10–15% permanent weight loss could lead to even grea-
ter gross per capita lifetime Medicare savings of $13,496
to $15,987 or $10,126–$13,474 over 10 years. Weight loss
of that magnitude followed by weight regain yields gross
per capita lifetime Medicare savings of $7,799–$11,109 or
$7,654–$8,534 over 10 years.
Finally, permanent weight loss of 10 to 15% for over-
weight beneficiaries (BMI ≥ 27) with diabetes or hyperten-
sion would be associated with a $9,445–$12,912 reduction
in gross per capita lifetime Medicare spending or $8,070–
$10,180 over 10 years. If the weight loss were temporary,
i.e., it were followed by 90% weight regain, gross per capita
lifetime Medicare savings would be $7,556–$9,933 or
$6,456–$7,831 over 10 years.
Aggregate savings are dependent upon many factors,
including the percentage of the Medicare population
that takes the drug, adherence rates, weight loss results,
etc. It is suggested that the reader develop his/her own
assumptions and apply them to the total pool of avai-
lable savings, which can be determined by multiplying
the number of potential beneficiaries in each respec-
tive BMI category and the per capita savings. For
example, from Table 1 it is evident that for class I
obesity (BMI ≥ 30), the available pool of savings asso-
ciated with 15% temporary weight loss (i.e., 90% of
the weight is re-gained over 10 years), is $49 billionover a 10-year period. If that weight loss were permanent,
the available savings pool is over $67 billion. Performing
the same calculations using 10% temporary and perman-
ent weight loss over 10 years yields a pool of available sa-
vings of almost $41 billion and $50 billion, respectively.
For class II obesity (BMI ≥ 35), the available pool of sa-
vings for 15% temporary and permanent weight loss over
10 years is $28 billion and more than $44 billion, respect-
ively; and for 10% temporary or permanent weight loss,
the available pool of savings is $25 billion and over $33
billion, respectively.
Discussion
These analyses estimate 10-year and lifetime gross per
capita savings when Medicare beneficiaries with over-
weight (and at least one weight-related comorbidity) and
obesity lose 10% or 15% of body weight, whether that
weight loss is temporary or permanent. Over ten years,
gross per capita savings to the Medicare program range
from $6,456 to $13,474 depending on BMI category, per-
cent weight loss, and sustainability of weight loss. Aggre-
gate savings to the Medicare program will depend on
the number of seniors with overweight and obesity who
take the medication, and the cost of drug to Medicare
each year. Sustained weight loss is difficult to achieve via
lifestyle intervention due to physiologic mediators of ap-
petite that encourage weight re-gain. Until recently, the
lack of effective medical therapies has left only bariatric
surgery as an option for some patients. However, new
obesity medications have the potential to produce and/
or sustain these levels of weight loss, and this provides
rationale and relevance for our analyses. Two obesity
drugs have recently been approved by the FDA, namely
phentermine/topiramate ER (QsymiaW) and lorcaserin
(BelviqW). The manufacturer of a third drug, bupropion
SR/naltrexone SR (ContraveW), has reached an agree-
ment with the FDA to conduct a pre-approval cardiovas-
cular outcomes trial.
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studied in patients with obesity (BMI ≥ 30 kg/m2) and
overweight (BMI of 27–29.9) with weight-related co-
morbidities, all of whom were provided lifestyle counsel-
ing and randomized to drug or placebo. While all three
drugs produce significant weight loss relative to placebo,
there is some variability in the degree of weight loss
achieved. Specifically, 1-year studies demonstrate that
lorcaserin treatment was associated with a 5.8% weight
loss compared to 2.2–2.8% for placebo [10,11], and bu-
propion SR/naltrexone SR led to 6.1 to 6.4% weight loss
as compared with 1.2–1.3% for placebo [12,13]. How-
ever, phentermine/topiramate ER produced the magni-
tude of weight loss that is in keeping with the savings
upon which our model is predicated (i.e., 9.8% weight
loss in patients with two or more comorbidities vs 1.2%
for placebo and 10.9% in severe/extreme obesity vs 1.6%
for placebo) [14,15]. Further, a long-term (2-year) clin-
ical trial found sustained weight loss with continued
treatment (SEQUEL), thus the gross per capita savings
may be more in line with the permanent weight loss
figures [8]. This trial also found reductions in fasting
glucose and fasting insulin, and resulted in a 54% and
76% (depending on the dose) reduction in the annua-
lized incidence rate for the progression to type 2 dia-
betes among all patients studied [8].
Because the fastest growing obesity category in the
United States includes those individuals with BMI > 50,
it is important to consider the potential efficacy of medi-
cation in this population. The EQUIP study is the only
phase III trial that did not specifically exclude subjects
with extreme obesity (i.e., BMI ≥ 45). The average BMI
of the study was 42, which represents the prototypical
patient who is referred for bariatric surgery. In this
population, one-year weight loss at the highest dose of
phentermine/topiramate ER was 10.9% (vs 1.6% for pla-
cebo) for the Intent-to-Treat (ITT) analysis and 14.4%
for Completers (vs 2.1% for placebo) [15]. Importantly
from both a clinical and cost perspective, significant
weight loss (8–10%) occurred within 3 months of treat-
ment, suggesting that non-responders may be identified
early. Two-thirds of treated subjects who completed one
year of therapy (“Completers”) achieved the NIH target
of ≥ 10% of body weight, and almost half lost ≥ 15%, re-
gardless of baseline BMI, suggesting that individuals with
extreme obesity can achieve significant weight loss with-
out surgery.
The CONQUER trial evaluated patients with a mi-
nimum of two obesity-related co-morbidities [14]. This
is somewhat analogous to the Medicare population, as
93% of Medicare beneficiaries have at least one obesity-
related condition [16]. The highest dose of phentermine/
topiramate ER achieved 9.8% and 12.4% weight loss after
one year in the ITT and Completer analyses, respectively,(vs 1.2% and 1.6% for placebo), and showed compara-
ble weight loss regardless of age (~10% of subjects were ≥
65 years of age) [14]. The one-year extension of this study
(SEQUEL) demonstrated the durability of the response
with sustained weight loss of 10.5% (vs 1.8% for placebo)
for the ITT analysis over the two-year period [8]. In each
of these studies, weight loss of this magnitude was associ-
ated with improvements in cardiometabolic risk factors,
including blood pressure, fasting glucose, fasting insulin
and lipid profiles, which is in keeping with the risk re-
ductions in our model upon which the Medicare savings
are based.
Table 1 indicates that each senior with obesity who
permanently loses 15% of weight saves Medicare, on
average, more than $12,000 in gross savings over a
10-year period. It is therefore evident that effectively
treating obesity with medication can be cost-effective.
Taking the average of the published Wholesale Acqui-
sition Costs (WAC) for both the recommended and
top dosage strengths of phentermine/topiramate ER,
and assuming a Medicare Part D tier-3 co-pay of $70
per month, net per capita savings to Medicare are an-
ticipated to be almost $3,000 over 10 years. Similar calcu-
lations for beneficiaries with class II obesity (BMI ≥ 35)
show even greater net per capita savings of almost $4,000
over 10 years. These net savings assume continual treat-
ment with phentermine/topiramate ER throughout the
10-year period because it is now recognized that obesity is
a chronic disease that requires ongoing intervention to
sustain weight loss. The chronic nature of obesity treat-
ment is recognized in the approved indication for phenter-
mine/topiramate ER, which is an adjunct to a reduced
calorie diet and increased physical activity for chronic
weight management in adults with obesity (BMI ≥ 30), or
overweight (BMI ≥ 27) with at least one weight-related co-
morbidity. The objective of pharmacotherapy is to coun-
teract the underlying pathology of obesity, which is the
dysregulation of physiologic mediators that affect appetite
and satiety. Discontinuation of pharmacotherapy after
successful weight loss removes this physiologic counter-
balance and is likely to lead to weight regain; hence, there
is no maximum time with respect to treatment duration,
regardless of the resulting BMI. This is analogous to the
continuation of anti-diabetic or anti-hypertensive therapy
after reaching an HbA1c target or adequately controlling
blood pressure. In both situations, therapy would be con-
tinued as the underlying pathology is still present.
It is important to note that these savings do not take
into consideration the reduction in dose or number of
concomitant medications used to treat the complications
of obesity, such as anti-hypertensive agents or drugs used
to treat type 2 diabetes. Clinical trials demonstrated that
patients taking phentermine/topiramate ER achieved re-
ductions in HbA1c and decreased blood pressure, despite
Thorpe et al. Health Economics Review 2013, 3:7 Page 5 of 6
http://www.healtheconomicsreview.com/content/3/1/7reductions in related medications aimed at reaching re-
commended therapeutic targets.
Conclusion
The Affordable Care Act added some additional preven-
tive benefits into the Medicare program. These benefits
include the elimination of cost sharing for certain clini-
cal prevention benefits, a new health risk appraisal, and
a personalized care plan. One specific benefit is coverage
of intensive behavioral therapy (IBT), which reimburses
primary care physicians for IBT of beneficiaries with
obesity for up to one year, provided the patients lose at
least 6.6 pounds during the first six months (approxi-
mately 3% of body weight using average baseline weight
of clinical trials). Yet, the current Medicare wellness be-
nefit remains incomplete since it does not include cover-
age for weight loss medications that have demonstrated
the ability to significantly improve risk factors associated
with cardiometabolic disease. Now that Medicare reim-
burses primary care physicians for IBT, it would seem
logical to also cover effective anti-obesity agents since
the combination of the two therapies is more success-
ful than either one individually. This combination could
prove a valuable strategy for providing sustained weight
loss, and with it, a reduction in overall health care
expenditures.
Medicare also provides coverage for bariatric surgical
procedures for patients with a BMI ≥ 35 who have at
least one weight-related comorbidity. New clinical devel-
opments include the approval of medications that can
produce weight loss of almost 15% in this population
of patients with severe and extreme obesity. Including
these medications in the Medicare benefit package would
fill the large treatment gap that exists between IBT and
bariatric surgery.
There are caveats with our results. The first is the rela-
tionship of drug dosage, treatment adherence and the
duration of weight loss. While weight loss produced by
phentermine/topiramate ER has demonstrated durabi-
lity over a two-year period of treatment, the results of
longer-term therapy are unknown, and the estimated
savings would be lower if weight loss is not sustained.
The top dose led to greater weight loss results, parti-
cularly in severe obesity, and patients who adhere to a
treatment regimen are more likely to achieve 10% and
15% weight loss, and sustain it over time. Therefore, we
believe our two scenarios, one with an initial weight loss
followed by 90% weight regain over 10 years, and the
other with permanent weight loss provide a reasonable
bound of the potential savings. In addition, aggregate
savings will depend on how many Medicare beneficiaries
in a particular group (e.g. BMI ≥ 30) use the weight loss
drug and achieve the same average result. FDA labe-
ling for newly approved agents requires a minimum 5%weight loss within a designated period of time or the pa-
tient should be considered a non-responder and the
drug discontinued. This should guard against excessive
medication costs without the commensurate health be-
nefits. Finally, although Table 1 figures do not include
the cost of the drug to the Medicare program and bene-
ficiaries, published WAC pricing and assumptions with
respect to average monthly co-pays provide reasonable
guidance for determining cost-effectiveness when com-
pared to per capita cost savings.
It is clear that 10–15% weight loss among individuals
with obesity has the potential to produce significant sa-
vings for the Medicare program. Currently, anti-obesity
drugs are an excluded category for coverage, while IBT
and bariatric surgery are covered benefits. This has re-
sulted in a significant treatment gap for the majority of
patients with obesity. The results of our analyses con-
firm that greater savings in health care spending will be
achieved by targeting the population with obesity as a
priority for weight management. It appears that this
could be achieved with the advent of effective anti-
obesity medications recently approved or under review
by the FDA.
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